Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduction-TR: Dapagliflozin in Severe Tricuspid Regurgitation
NCT05686616Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in tricuspid regurgitation (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Right Ventricular End Systolic Volume Index at 12 months. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
tricuspid regurgitation
Beyond the preview
Go deeper on NCT05686616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686616.